Foghorn Therapeutics Inc.
corporate_fare Company Profile
Foghorn Therapeutics Inc. (NASDAQ:FHTX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 15 items for FHTX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-09, rated 7/10. Across its 15 most recent items scored 7 or higher, the top rating is 9/10, with 12 rated 8 or above. Recent SEC coverage for FHTX spans 8-K, 10-Q, DEF 14A, 10-K.
Recent high-impact activity:
- Foghorn Swings to $58.2M Q3 Profit on $74.1M Catch-Up Adjustment, Cash Runway to 2029
- Foghorn Swings to $58.2M Q3 Net Income, Extends Cash Runway to 2H 2029
- Foghorn Halts FHD-909 and SMARCA2 Programs, Cuts 40% of Workforce
- Foghorn Halts FHD-909, Cuts 40% of Staff, Extends Runway to 2029
- Foghorn Therapeutics Q1 Revenue Plunges 45% to $3.3M, Net Loss Widens
Financial Snapshot
Short Interest & Short Volume
3.90 days to coverFINRA reported short interest of 2,251,943 shares in FHTX as of the October 30, 2026 settlement, a 8.3% decrease from the prior period — about 3.9 days to cover at its recent average daily volume. On November 20, 2026, 31.0% of FHTX volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.